181 related articles for article (PubMed ID: 12002714)
21. Correlation of Quantitative
Harapoz M; Evans S; Geenty P; Kwok F; Stewart G; Taylor MS; Farlow D; Thomas L
Heart Lung Circ; 2022 Jun; 31(6):804-814. PubMed ID: 35181228
[TBL] [Abstract][Full Text] [Related]
22. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
[TBL] [Abstract][Full Text] [Related]
23. Cardiac transthyretin amyloidosis
Löfbacka V; Axelsson J; Pilebro B; Suhr OB; Lindqvist P; Sundström T
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1822-1832. PubMed ID: 33367948
[TBL] [Abstract][Full Text] [Related]
24. DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker.
Scully PR; Morris E; Patel KP; Treibel TA; Burniston M; Klotz E; Newton JD; Sabharwal N; Kelion A; Manisty C; Kennon S; Ozkor M; Mullen M; Hartman N; Elliott PM; Pugliese F; Hawkins PN; Moon JC; Menezes LJ
JACC Cardiovasc Imaging; 2020 Jun; 13(6):1353-1363. PubMed ID: 32498921
[TBL] [Abstract][Full Text] [Related]
25. Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.
Glaudemans AW; van Rheenen RW; van den Berg MP; Noordzij W; Koole M; Blokzijl H; Dierckx RA; Slart RH; Hazenberg BP
Amyloid; 2014 Mar; 21(1):35-44. PubMed ID: 24455993
[TBL] [Abstract][Full Text] [Related]
26. Does [99mTc]-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) soft tissue uptake allow the identification of patients with the diagnosis of cardiac transthyretin-related (ATTR) amyloidosis with higher risk for polyneuropathy?
Wollenweber T; Kretschmer-Chott E; Wurm R; Rasul S; Kulterer O; Rettl R; Duca F; Bonderman D; Sühs KW; Hacker M; Traub-Weidinger T
J Nucl Cardiol; 2023 Feb; 30(1):357-367. PubMed ID: 35817943
[TBL] [Abstract][Full Text] [Related]
27. The Utility of
Moore PT; Burrage MK; Mackenzie E; Law WP; Korczyk D; Mollee P
Heart Lung Circ; 2017 Nov; 26(11):1183-1190. PubMed ID: 28256403
[TBL] [Abstract][Full Text] [Related]
28. Noninvasive risk stratification of patients with transthyretin amyloidosis.
Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
[TBL] [Abstract][Full Text] [Related]
29. The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease.
Azevedo Coutinho MC; Cortez-Dias N; Cantinho G; Gonçalves S; Menezes MN; Guimarães T; Lima da Silva G; Francisco AR; Agostinho J; Santos L; Conceição I; Pinto FJ
Amyloid; 2020 Sep; 27(3):174-183. PubMed ID: 32482106
[No Abstract] [Full Text] [Related]
30. Letter to the editor concerning "Cardiac [99mTc]Tc-hydroxydiphosphonate uptake on bone scintigraphy in patients with hereditary transthyretin amyloidosis: an early follow-up marker?".
Yu AL; Tsai CH; Cheng MF; Lin YH
Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2161-2162. PubMed ID: 38653815
[No Abstract] [Full Text] [Related]
31. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
Chen W; Ton VK; Dilsizian V
Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
[TBL] [Abstract][Full Text] [Related]
32. Role of cardiac scintigraphy with ⁹⁹mTc-DPD in the differentiation of cardiac amyloidosis subtype.
de Haro-del Moral FJ; Sánchez-Lajusticia A; Gómez-Bueno M; García-Pavía P; Salas-Antón C; Segovia-Cubero J
Rev Esp Cardiol (Engl Ed); 2012 May; 65(5):440-6. PubMed ID: 22464102
[TBL] [Abstract][Full Text] [Related]
33. Cardiac scintigraphy with
de Haro-Del Moral FJ; Pubul-Núñez V; Casáns-Tormo I; Jiménez-Heffernan A; Ruano-Pérez R
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):254-266. PubMed ID: 32513587
[TBL] [Abstract][Full Text] [Related]
34. Serial scanning with
Minutoli F; Di Bella G; Mazzeo A; Laudicella R; Gentile L; Russo M; Vita G; Baldari S
J Nucl Cardiol; 2021 Oct; 28(5):1949-1957. PubMed ID: 31741327
[TBL] [Abstract][Full Text] [Related]
35. 99mTc DPD is the preferential bone tracer for diagnosis of cardiac transthyretin amyloidosis.
Rossi P; Tessonnier L; Frances Y; Mundler O; Granel B
Clin Nucl Med; 2012 Aug; 37(8):e209-10. PubMed ID: 22785530
[TBL] [Abstract][Full Text] [Related]
36. Cardiac denervation evidenced by MIBG occurs earlier than amyloid deposits detection by diphosphonate scintigraphy in TTR mutation carriers.
Piekarski E; Chequer R; Algalarrondo V; Eliahou L; Mahida B; Vigne J; Adams D; Slama MS; Le Guludec D; Rouzet F
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1108-1118. PubMed ID: 29511839
[TBL] [Abstract][Full Text] [Related]
37. 99mTc-DPD scintigraphy and SPECT/CT in patients with AL and ATTR type amyloidosis: Potential clinical implications.
Lee J; Kim K; Choi JO; Kim SJ; Jeon ES; Choi JY
Medicine (Baltimore); 2020 Jan; 99(4):e18905. PubMed ID: 31977903
[TBL] [Abstract][Full Text] [Related]
38. Non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis.
Sperry BW; Gonzalez MH; Brunken R; Cerqueira MD; Hanna M; Jaber WA
J Nucl Cardiol; 2019 Oct; 26(5):1630-1637. PubMed ID: 29344917
[TBL] [Abstract][Full Text] [Related]
39. Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy.
Longhi S; Guidalotti PL; Quarta CC; Gagliardi C; Milandri A; Lorenzini M; Potena L; Leone O; Bartolomei I; Pastorelli F; Salvi F; Rapezzi C
JACC Cardiovasc Imaging; 2014 May; 7(5):531-2. PubMed ID: 24831216
[No Abstract] [Full Text] [Related]
40. [Cardiac involvement in systemic amyloidosis: myocardial scintigraphic evaluation].
Hongo M; Yamada H; Okubo S; Hirayama J; Fujii T; Kusama S; Ikeda S
J Cardiogr; 1985 Mar; 15(1):163-80. PubMed ID: 2999267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
